Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials

J Am Acad Dermatol. 2025 May 27:S0190-9622(25)02204-2. doi: 10.1016/j.jaad.2025.05.1422. Online ahead of print.

¹ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois. Electronic address: APaller@nm.org.
² Department of Pediatrics, Saint Louis University, St. Louis, Missouri; Cardinal Glennon Children's Hospital, St. Louis, Missouri.
³ Department of Infection, Immunity and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield, Sheffield, United Kingdom; Children's Hospital, Sheffield, United Kingdom.
⁴ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
⁵ Lydia Becker Institute of Immunology & Inflammation, University of Manchester, Manchester, United Kingdom.
⁶ DERMAPOLIS Medical Dermatology Center, Chorzów, Poland.
⁷ Regeneron Pharmaceuticals Inc, Tarrytown, New York.
⁸ Sanofi, Cambridge, Massachusetts.

No abstract available

Keywords: atopic dermatitis; biomarkers; dupilumab; erythrodermic; pediatric eczema.